10x Genomics Files 8-K on Officer/Director Changes
Ticker: TXG · Form: 8-K · Filed: Jan 16, 2024 · CIK: 1770787
| Field | Detail |
|---|---|
| Company | 10x Genomics, Inc. (TXG) |
| Form Type | 8-K |
| Filed Date | Jan 16, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001, $14,335 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, corporate-governance
TL;DR
**10x Genomics just filed an 8-K about executive changes, keep an eye on leadership shifts.**
AI Summary
10x Genomics, Inc. filed an 8-K on January 16, 2024, reporting an event that occurred on January 15, 2024. This filing indicates changes related to the departure or election of directors, appointment of officers, or compensatory arrangements for certain officers. While specific names or dollar amounts are not detailed in the provided text, this type of filing is important for investors as it signals potential shifts in leadership or executive compensation, which can impact the company's strategic direction and financial health.
Why It Matters
Changes in leadership or executive compensation can signal strategic shifts or financial implications, directly influencing investor confidence and the company's future performance.
Risk Assessment
Risk Level: medium — The filing indicates changes in leadership or compensation, which can introduce uncertainty or signal strategic shifts, warranting investor attention.
Analyst Insight
Investors should monitor future filings or company announcements from 10x Genomics, Inc. for specific details regarding the reported changes in leadership or compensation, as these could impact the company's strategic direction and financial outlook.
Key Numbers
- $0.00001 — Par value per share (Par value of 10x Genomics, Inc. Class A common stock)
Key Players & Entities
- 10x Genomics, Inc. (company) — the registrant filing the 8-K
- January 15, 2024 (date) — date of the earliest event reported
- January 16, 2024 (date) — date the 8-K was filed
- TXG (company) — trading symbol for 10x Genomics, Inc.
- The Nasdaq Stock Market LLC (company) — exchange where Class A common stock is registered
- $0.00001 (dollar_amount) — par value per share of Class A common stock
Forward-Looking Statements
- Further details regarding the specific changes in directors, officers, or compensatory arrangements will be disclosed in subsequent filings or company announcements. (10x Genomics, Inc.) — high confidence, target: Q1 2024
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 15, 2024.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on January 16, 2024.
What is the trading symbol for 10x Genomics, Inc.?
The trading symbol for 10x Genomics, Inc. is TXG.
On which exchange is 10x Genomics, Inc.'s Class A common stock registered?
10x Genomics, Inc.'s Class A common stock is registered on The Nasdaq Stock Market LLC.
What is the par value per share of 10x Genomics, Inc.'s Class A common stock?
The par value per share of 10x Genomics, Inc.'s Class A common stock is $0.00001.
Filing Stats: 545 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-01-16 16:07:19
Key Financial Figures
- $0.00001 — tered Class A common stock, par value $0.00001 per share TXG The Nasdaq Stock Market
- $14,335 — and a one time COBRA-related payment of $14,335. Dr. Wilbur will not receive an annual
Filing Documents
- txg-20240115.htm (8-K) — 25KB
- txg-20240115_g1.jpg (GRAPHIC) — 223KB
- 0001770787-24-000007.txt ( ) — 661KB
- txg-20240115.xsd (EX-101.SCH) — 2KB
- txg-20240115_lab.xml (EX-101.LAB) — 23KB
- txg-20240115_pre.xml (EX-101.PRE) — 12KB
- txg-20240115_htm.xml (XML) — 3KB
02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On January 15, 2024, Chief Commercial Officer James Wilbur and 10x Genomics, Inc. (the "Company") entered into a Transition and Separation Agreement (the "Agreement") pursuant to which Dr. Wilbur will depart the Company on February 1, 2024. Dr. Wilbur's departure is not due to any disagreement with the Company's management team, operations, financial statements, policies or procedures. Pursuant to the Agreement, Dr. Wilbur will be awarded a one time severance payment of an amount equal to six months of his base salary and a one time COBRA-related payment of $14,335. Dr. Wilbur will not receive an annual performance bonus for the full year 2023. Such payments and benefits are conditioned upon Dr. Wilbur continuing to comply with certain obligations applicable to him and, upon execution and termination, delivery and non-revocation of a general release of claims. The above description of the Agreement is not complete and is qualified in its entirety by reference to the text of the Agreement, which the Company expects to file as an exhibit to its Annual Report on Form 10-K for the year ended December 31, 2023.
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 10x Genomics, Inc. By: /s/ Eric S. Whitaker Name: Eric S. Whitaker Title: Chief Legal Officer Date: January 16, 2024